Elysium Therapeutics
AKRON, OH · Biotechnology, Healthcare · 4 employees
Elysium Therapeutics is a clinical-stage biopharmaceutical company focused on reducing suffering from severe acute pain, opioid-use disorder, and fatal opioid overdose by developing first- or best-in-class therapies that address the fundamental safety and abuse limitations of today’s opioids. Through its differentiated platforms—O2P™ for oral overdose protection, XpiRx™ for time-limited opioid pot
Funding history
- Funding Round — $7.5M — Jan 2026
- Series seed — $2.2M — Oct 2022
- Funding Round — $915K — Nov 2020
- Funding Round — $932K — Sep 2018
- Funding Round — $2.2M — Dec 2017
Recent signals
- Jan 28, 2026: Raised $7.5M
- Oct 11, 2022: Raised $2.2M in Series seed
- Nov 16, 2020: Raised $915K
- Sep 20, 2018: Raised $932K
- Dec 22, 2017: Raised $2.2M
See plans & pricing → Track Elysium Therapeutics’s funding, hiring, and signals — with verified contacts — on Fundz.